Celltrion today announced that Health Canada has approved Omlyclo™, a biosimilar referencing Xolair®. Omlyclo™ is approved ...
Celltrion's asthma treatment Omlyclo, a biosimilar of Novartis's Xolair, has received Canadian approval for chronic urticaria, rhinosinusitis, and allergic asthma ...
A new study published in the Ear, Nose and Throat Journal found that the severity of chronic rhinosinusitis with nasal ...
IT’S that time of year where we’re greeted by a cacophony of coughs, sneezes and sniffles wherever we go. You might think a cough is a cough, but different conditions will produce a ...